Combined Adjuvant of Poly I:C Improves Antitumor Effects of CAR-T Cells

Chimeric antigen receptor modified T cells (CAR-T) therapy is an emerging immunotherapy against malignancies. However, only limited success was obtained in solid tumors. Polyinosinic-polycytidylic acid (poly I:C), ligand of TLR3, mediates innate immune and adaptive immune and shows broad antitumor e...

Descripción completa

Detalles Bibliográficos
Autores principales: Di, Shengmeng, Zhou, Min, Pan, Zeyan, Sun, Ruixin, Chen, Muhua, Jiang, Hua, Shi, Bizhi, Luo, Hong, Li, Zonghai
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2019
Materias:
Oncology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6481273/
https://www.ncbi.nlm.nih.gov/pubmed/31058074
http://dx.doi.org/10.3389/fonc.2019.00241

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6481273/
https://www.ncbi.nlm.nih.gov/pubmed/31058074
http://dx.doi.org/10.3389/fonc.2019.00241

Ejemplares similares